DelveInsight’s ‘Beta Thalassemia—Market Insights, Epidemiology, and Market Forecast—2032’ report delivers an in-depth understanding of Beta Thalassemia, historical and forecasted epidemiology as well as the market trends in the United States and EU5 (Germany, Spain, Italy, France, and the United Kingdom).
Key Highlights of Beta Thalassemia Market
The Key Companies working in the Beta Thalassemia market include Novartis, Merck, Agios Pharma and many others
The Key Therapies working in the Beta Thalassemia market include Mitapivat (AG-348), Zynteglo (LentiGlobin BB305), and many others.
Beta Thalassemia Overview
Beta thalassemia is a blood disorder characterized by reduced synthesis of the hemoglobin subunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheral blood smear with nucleated red blood cells, and reduced amounts of hemoglobin A (HbA) on hemoglobin analysis. Beta Thalassemia is an inherited disorder caused due to genetic modification (deletion/alteration) on Chromosome 11. The major risk factors include “Family history of the disorder” and /or “Asian, Chinese, Mediterranean, or African American ethnicity.”
Beta Thalassemia Epidemiology Insights
Eastern Mediterranean: 2-18% of the population is affected by a gene mutation.
Europe: 0-19% of the population is affected by a gene mutation.
Southeast Asia: 0-11% of the population is affected by a gene mutation.
Sub-Saharan Africa: 0-12% of the population is affected by a gene mutation.
Click here to learn more about the Beta Thalassemia Market Landscape
The Report Covers the Beta Thalassemia Epidemiology Segmented by:
Beta Thalassemia diagnosed cases
Total Beta Thalassemia incident cases
Total Beta Thalassemia prevalent cases
Beta Thalassemia treatment cases
Beta Thalassemia Market Outlook
The report’s Beta Thalassemia market outlook helps to understand the historical, current and forecasted Beta Thalassemia market trends by analyzing the impact of current therapies on the market, unmet needs, SWOT analysis, and demand for better technology.
This segment gives a holistic analysis of the Beta Thalassemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight.
According to DelveInsight, the Beta Thalassemia market in 6MM is expected to grow steadily during the study period 2019–2032.
Key Companies Working in the Beta Thalassemia Market
Novartis
Merck
Bristol Myers Squibb
Chiesi Farmaceutici S.p.A
Bluebird Bio
Agios Pharmaceuticals
And many others
Beta Thalassemia Therapies Covered and Analyzed in the Report
Mitapivat (AG-348)
Zynteglo (LentiGlobin BB305)
Learn more about the Key Companies and Emerging Therapies in the Beta Thalassemia Market
Table of Contents
Key Insights
Beta Thalassemia Introduction
Executive Summary of Beta Thalassemia
Disease Background and Overview
Epidemiology and patient population
Beta Thalassemia Emerging Therapies
Market Access and Reimbursement of Therapies
Market Drivers
Market Barriers
Appendix
Report Methodology
DelveInsight Capabilities
Disclaimer
Learn about the detailed offerings of the report @ Beta Thalassemia Market Outlook
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: 919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
